September 19, 2020

The Niche

Knoepfler lab stem cell blog

GVHD

6 min read

Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow transplant (BMT). Eighty Percent Mortality BMT has been used for more than half a century to treat and possibly cure certain cancers and single-gene conditions like sickle cell disease, …Read More

11 min read

Today’s post is an interview I did with Dr. Van Bokkelen covering 10 questions. Dr. Gil Van Bokkelen is Chairman and CEO of Athersys, Inc., a company that has focused heavily on stem cells and regenerative medicine for more than a decade. For more on Dr. Van Bokkelen’s background see additional bio section at the end of this post. 1. Why stem cells? Of all the biotech areas you could have worked on, what inspired you to work on stem cells? Was there a defining moment, …Read More